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C A S E  R E P O R T
A 78-year-old gentleman presented with Canadian Cardiological Society (CCS) 
class III angina and had been getting excruciating substernal pain while walking 50 
to 100 m on the flat over the last 15 days despite optimal medical therapy. From his 
past medical history the patient underwent CABG in 1997 (LIMA to LAD and SVG 
to dominant RCA); in 2006 he had an angioplasty done in his SVG and stents were 
implanted (no medical data regarding the angioplasty were found). Cardiac enzymes 
and troponin were negative; a mild increase of creatinine was noted on admission. The 
echocardiogram revealed severe basal inferior wall hypokinesia with overall reasonably 
preserved left ventricular and right ventricular systolic function.
The patient was catheterized and patent LIMA graft to LAD was found; the SVG 
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AbbreviAtions
BMS = bare metal stent(s)
CCS = Canadian Cardiological Society
DES = drug-eluting stent(s)
LAD = left anterior descending
LIMA = left internal mammary artery
PCI = percutaneous coronary intervention
RCA = right coronary artery
SVG = saphenous vein graft
TLR / TVR = target lesion/vessel 
revascularization
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FIGURE 1. ECG on admission.
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a BMW 0.014-inch guidewire was used. The following balloons 
were selected: Sprinter 1.25 x 6 mm, NC Durastar 4.0 x 10 mm, 
NC Trek 5.0 x 15 mm, Cutting balloon (Boston Scientific) 4.0 
x 15 mm. A manual thromboaspiration catheter (Export AP 
6 Fr) was employed. Finally 2 long drug-eluting stents (DES) 
were implanted (Endeavor Resolute 3.5x 38 mm and Endeavor 
Resolute 3.5 x 30mm).
P R O C E D U R E
The guidewire supported by a small balloon 1.25x 6mm 
passed throught the occlusion with some difficulty and multiple 
passages with an Export thromboaspiration catheter were 
carried out immediately after without predilatation. Due to 
high thrombotic burden 2 mg of tenecteplase and 500 μg of 
adenosine to protect the distal microvasculature were admin-
istered through the distal lumen of the thromboaspiration 
catheter. Beyond the high thrombus grade there was diffuse 
in stent restenosis and multiple cutting balloon dilatations 
were utilized. Two long minimally overlapping stents (DES) 
were deployed accompanied by multiple very high pressure 
post dilatations with 4.0 and 5.0 mm NC balloons up to 30 
bar. The final angiographic result although not perfect was 
acceptable with 20-30% residual stenosis, TIMI III flow and 
blush grade III.
D I S C U S S I O N
Percutaneous SVG intervention is a feasible treatment 
strategy despite the fact that the procedure is extremely chal-
FIGURE 1. Total occlusion of right coronary artery (RCA).
FIGURES 2 and 3. Totally occluded SVG proximally. SVG = saphenous vein graft.
graft was totally occluded in its proximal segment and also 
the native RCA was totally occluded proximally (chronic total 
occlusion). A small left circumflex and intermediate branch 
had no significant disease.
In view of the unstable clinical syndrome and the angio-
graphic findings we decided to proceed with angioplasty to the 
SVG. A multipurpose A1 6F guiding catheter was utilized and 
88
HOSPITAL CHRONICLES 2010, VOLUME 7, SUPPLEMENT 1: «ATHENS CARDIOLOGY UPDATE 2012»
lenging due to high rates of periprocedural adverse events 
(slow-flow, no-reflow, myocardial infarction), increased 
restenosis rate and accelerated atheromatous SVG disease 
beyond the treated segments. The decision was made to treat 
the SVG instead of recanalization of the native RCA because 
of many unfavourable anatomic characteristics of this 14-year 
old chronic total occlusion. A number of studies showed sober-
ing results in SVG intervention and probably one may opt for 
native vessel PCI if that is feasible.
In our case we had to solve two pathophysiologically 
distinct issues. The high thrombotic burden on one hand and 
also the diffuse in stent restenotic process on the other hand. 
Acute or subacute totally occlusive with high thrombus grade 
diffuse in stent restenosis in SVGs deserves a special mention 
FIGURE 7. Final result with blush grade III ( arrows).
FIGURE 6. Final result with TIMI III flow.FIGURE 4. Diffuse in stent restenosis and high thrombotic bur-
den.
FIGURE 5. Previously deployed stents in SVG (arrows). SVG = 
saphenous vein graft.
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FIGURE 8. ECG pre discharge.
since there is currently little scientific data applicable to this 
subset of lesions.
We performed, right from the outset, manual thromboaspi-
ration with a 6F Export AP catheter (without pre-dilation) 
with multiple passages and also via the central lumen of the 
aspiration catheter we administered 2 mg of tenecteplase and 
repeated bolus doses of adenosine (up to 500 μg) as a �phar-
macological distal protection regimen’. Although prophylactic 
adenosine injections in small boluses (>5 boluses of 24 μg) 
through the guiding catheter prior to SVG intervention was 
not found to be protective for the no- reflow phenomenon,1 
we administered it locally through the Export AP catheter in 
high doses with excellent microvasculature protective effect 
and post procedure blush grade III.
Brodie et al found a higher in-hospital mortality (21.1% 
vs 8%, p=0.0004) in patients treated for acute thrombotic 
SVG occlusion as compared to thrombotic occlusion of native 
coronary arteries.2 There are no randomized trials regarding 
the long term effectiveness and long term prognosis in percuta-
neous SVG re-interventions due to diffuse in stent restenosis. 
Although this subset of lesions are infrequent in daily practice 
we need more data in order to be able to offer our patients 
the best treatment strategy.
We did not utilize embolic protection device in our case 
despite the class I ACC/AHA guideline recommendation 
for a number of reasons. Firstly, because we did not have 
one immediately available on the shelf and the patient was 
unstable. Secondly, the vein graft was totally occluded with 
severe and diffuse in stent hyperplasia and high amount of 
thrombotic material which could have made distal protection 
devices extremely difficult to place with a disease free landing 
zone. Probably, a proximal protection device such as Proxis 
might have been useful. Thirdly, it is known that protection 
devices are underused worldwide approximately in 23% of 
SVG interventions.3,4
Although we did not know the type of stents used in the 
previous intervention we made up our minds to implant second 
generation DES (zotarolimus). The safety and efficacy of DES 
vs BMS remains uncertain due to contradictory reports of 
either TLR and TVR with DES or a probable excess of clini-
cal events with DES.5,6 Nonetheless some available evidence 
supports treatment with DES in this high risk lesion subset.7-15
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